{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:59Z","timestamp":1777934699676,"version":"3.51.4"},"reference-count":18,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T00:00:00Z","timestamp":1717718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Rituximab is a chimeric monoclonal antibody used to treat a range of malignant and benign haematological conditions. To minimise the risk of infusion-related toxicity, initial infusions are administered slowly over 4\u20136\u2005h. In the absence of significant reactions, subsequent doses are often administered over an off-label rate of 90\u2005min. In response to emergent data, our site adopted the use of rapid 60-min infusions for third and subsequent doses. This study aimed to review the safety and ongoing feasibility of 60-min rituximab infusions following institutional practice change.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pharmacy dispensing records were used to identify all rituximab infusions dispensed under the direction of a haematologist between 1 January 2023 and 30 June 2023. Electronic medical records were reviewed retrospectively to characterise the incidence of infusion reactions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight-two patients received a total of 262 rituximab infusions, including 54 patients who received a total of 113 rapid 60-min infusions. No infusion-related reactions were observed with 60-min administration. Five patients who experienced grade 1\u20132 infusion reactions with their first or second dose of rituximab safely received 60-min infusions for third and subsequent doses without additional premedication. Indications for treatment included non-Hodgkin's lymphoma (76.99%), non-malignant disease states (17.70%), chronic lymphocytic leukaemia (3.54%) and post-transplant lymphoproliferative disorder (1.77%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In the absence of severe reactions to initial and second doses, administration of rituximab over 60\u2005min is well tolerated in patients with malignant and benign haematological disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552241260863","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T05:22:23Z","timestamp":1717737743000},"page":"780-784","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Rapid rituximab administration: Safety of 60-minute infusions in malignant and benign haematological disease"],"prefix":"10.1177","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7261-6122","authenticated-orcid":false,"given":"Rebecca","family":"Whiting","sequence":"first","affiliation":[{"name":"Pharmacy Department, Fiona Stanley Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-2683","authenticated-orcid":false,"given":"Jeanie","family":"Misko","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Fiona Stanley Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"McGuire","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Fiona Stanley Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Fox","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Fiona Stanley Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,6,7]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Australian Product Information \u2013 Riximyo\u00ae (Rituximab) Concentrated Solution for Injection. 2023."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14062"},{"key":"e_1_3_3_4_2","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute 2017."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.877135"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-11-059469"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2006.00713.x"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.8.2153"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj103"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2009.01215.x"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2869-4"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1124"},{"key":"e_1_3_3_13_2","first-page":"863909","article-title":"Infusion rate escalation study of rituximab in patients with CD20+ B-cell lymphomas: a single institution analysis in Japan","volume":"2013","author":"Yokoyama M","year":"2013","unstructured":"Yokoyama M, Terui Y, Takeuchi K, et al. Infusion rate escalation study of rituximab in patients with CD20+ B-cell lymphomas: a single institution analysis in Japan. ISRN Oncol 2013; 2013: 863909.","journal-title":"ISRN Oncol"},{"key":"e_1_3_3_14_2","unstructured":"EviQ Rituximab Infusion Table ID: 3044 v.4. 2023. Available from: https:\/\/www.eviq.org.au\/additional-clinical-information\/3044-rituximab-infusion-table."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1788-5"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220978450"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13604"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.812"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-160028"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241260863","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552241260863","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552241260863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:57Z","timestamp":1777688997000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552241260863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,7]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/10781552241260863"],"URL":"https:\/\/doi.org\/10.1177\/10781552241260863","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,7]]}}}